Purpose: This multicenter, prospective study investigates the efficacy and safety of lacosamide adjunctive therapy in pediatric and adult patients with uncontrolled epilepsy. Method: This study was carried out between September 2010 and December 2011 at 16 Italian and 1 German neurologic centers. Lacosamide was added to the baseline therapy at a starting dose of 1 mg/kg/ day in patients aged <16 years (group A) and 100 mg daily in subjects aged 16 and older (group B), and titrated to the target dose, ranging from 3 to 12 mg/kg/day or from 100 to 600 mg daily, respectively. After completing the titration period, patients entered a 12-month maintenance period and they were followed up at 3, 6 and 12 months. The primary assessment of efficacy was based on the change from baseline in seizure frequency per 28 days and was evaluated at 3, 6 and 12 months as follows: number and proportion of 100% responders, 50% responders, non-responders and worsening patients. Safety evaluation was also performed at 3, 6 and 12 months. Results: A total of 118 patients (59 group A, 59 group B) with uncontrolled generalized and focal epilepsy were enrolled. Patient mean AE SD age was 15.9 AE 6.80 years and the age range was 4-38 years. At 3-month evaluation, of 118 treated patients 56 subjects (47.4% group A; 47.4% group B; p = 0.8537) experienced at least a 50% reduction in seizure frequency. At 6 and 12-month follow-up, the 50% responders were 57 (52.5% group A; 44.1% group B; p = 0.4612) and 51 (47.4% group A; 39% group B; p = 0.4573), respectively. Thirty-five subjects (30.5% group A; 28.8% group B; p = 1) experienced side effects during the treatment period. The most common adverse events were dyspepsia for group A and dizziness for group B. Conclusion: Lacosamide may be a useful and safe pharmacological treatment option for both pediatric and adult patients with uncontrolled seizures.
Introduction

Lacosamide was approved in August 2008 by the European Commission and in October 2008 by the Food and Drug
Administration as an adjunctive therapy for partial onset seizures in patients with epilepsy aged 16 and older (Europe)/17 and older (United States).
Lacosamide ([R]-2-acetamido-N-benzyl-3-methoxypropionamide) is a unique functionalized amino acid specifically synthesized for use as an antiepileptic drug (AED). 1, 2 It is available in dose-equivalent oral and intravenous formulations. 3 Initial investigations suggested that LCM might have two mechanisms of action: increase of the slow inactivation of the voltage-gated sodium channels and interference with collapsingresponse mediator protein 2 (CRMP-2).
1,4-6 However, the CRMP-2 component has recently been refuted based on new experimental evidence. 7 Three large phase IIb/III randomized, placebo-controlled trials were carried out to evaluate the clinical utility of oral lacosamide as adjunctive therapy for refractory partial-onset seizures in adults aged 16-70 years. [8] [9] [10] Initially, a phase IIb multinational trial (SP667) evaluated lacosamide 200, 400, and 600 mg/day compared with placebo as adjunctive treatment in 418 adults with uncontrolled partial onset seizures taking 1-2 concomitant AEDs. 8 Reductions in seizure frequency and the proportion of patients with at least a 50% reduction in seizure frequency (50% responder rate) with lacosamide 400 and 600 mg/ day were statistically significant compared with placebo in the primary intent-to-treat (ITT) population. 8 Two additional phase III trials (SP755 and SP754) were conducted in parallel to confirm these results in an expanded population of patients, taking up to three AEDs with or without additional vagus nerve stimulation. 9, 10 The potential usefulness of lacosamide in pediatric patients with uncontrolled seizures has been investigated in four small recent studies. [11] [12] [13] [14] To the best of our knowledge, there is no study comparing the usefulness of lacosamide treatment in adults and children. The purpose of the present multicentric study was to evaluate the safety and efficacy of lacosamide adjunctive therapy in both pediatric and adult populations.
Materials and methods
The present report is a multicenter, prospective, open-label treatment study carried out between September 2010 and December 2011 at 16 Italian and 1 German centers.
The study protocol, amendments and informed consent were reviewed by ethics committees for each site. All patients or their legal representatives gave written informed consent before study participation.
Males and females, aged between 4 and 40 years, with uncontrolled generalized and focal epilepsy were eligible. Diagnosis was based on the classification of epileptic seizures (Commission on Classification and Terminology of the International League Against Epilepsy, 2005-2009). 15 Inclusion criteria required patients to have had at least a 1-year history of epileptic seizures despite treatment with at least two AEDs (concurrently or sequentially). During the 12-week period before enrollment, patients were to have had at least 2 seizures per 28 days on average. In addition, patients were to have been taking a stable dosage regimen of 1-4 AEDs, with or without vagus nerve stimulation (VNS), in the 4 weeks before enrollment.
The following exclusion criteria were applied: age less than four years, metabolic and systemic disorders, poor compliance, refused informed consent. Females who were pregnant, breast-feeding, or of childbearing potential and not using approved contraception methods were also excluded.
After enrollment, plasma samples were drawn to investigate complete blood count (CBC), transaminasemia, azotemia, glycemia, gamma gt levels, PT and PTT tests, fibrinogen levels, serum cholesterol levels, triglyceride levels, electrolytes balance, serum thyroid hormones; urinalysis, sleep/awake EEG, ECG and brain RMN were also performed.
Seizure frequency during the 4 weeks preceding lacosamide initiation was used as baseline. All patients were divided into two groups: group A (age < 16 years) taking lacosamide off-label and group B (age ! 16 years). Lacosamide was added to a stable dosage of baseline AEDs and administered orally in the form of syrup or tablets. Lacosamide was initiated at 1 mg/kg/day in the group A and 100 mg/day in the group B and titrated in 1 mg/kg/day or 50 mg/day increments per week until the target dose, ranging from 3 to 12 mg/kg/day or from 100 to 600 mg/day respectively, was met. During the titration period, all patients were reviewed every 2 weeks.
After the titration period, patients entered a 12-month maintenance period and were followed up at 3, 6 and 12 months. No change in the dose of lacosamide was permitted during the maintenance period.
Patients who were unable to tolerate protocol medication and those experiencing an increase in seizure frequency or status epilepticus were to discontinue treatment.
The primary assessment of efficacy was based on the change from baseline in seizure frequency per 28 days and was evaluated at 3, 6 and 12-month follow-up, as follows: number and proportion of patients achieving seizure freedom (100% responders); number and proportion of patients experiencing a 50% or greater reduction in seizure frequency (50% responders); number and proportion of patients experiencing less than 50% reduction in seizure frequency (non-responders); number and proportion of patients having an increase in seizure frequency (worsening patients). Afterwards patients were divided into exclusive categories of seizure type (generalized seizures; focal seizures; focal evolving to bilateral convulsive seizures; mixed seizures which included patients experiencing either generalized and focal seizures) and the efficacy outcomes were analyzed according to this classification. Patients or their caregiver kept daily diaries, which documented seizure types and seizure frequency from the beginning of baseline until the last evaluation.
The assessment of safety was performed at 3, 6 and 12 months and consisted in collecting data on adverse events reported by the patient or their caregiver or observed by the investigator; patient withdrawals due to adverse events; changes in laboratory values (CBC, liver and kidney function tests, urinalysis, plasma concentrations of concomitant AEDs), ECG and EEG, vital sign and body weight measurements, physical and neurologic examination findings.
Efficacy and safety outcomes between group A and group B were compared using the chi-squared test.
Statistical significance was based on a probability level (a) equal to 0.05. All analyses were performed using the statistical programming language R.
Results
Demographics
A total of 118 patients (59 group A, 59 group B) with uncontrolled generalized and focal epilepsy were enrolled. Of 118 patients entering the study, all subjects completed the titration phase and 81 patients completed the maintenance phase. Of 37 (31.4%) patients discontinuing prematurely (22% group A; 40.7% group B; p = 0.0472), 18 (15.2%) withdrew from the study due to lack of efficacy (6.8% group A; 23.7% group B; p = 0.0212), 12 (10.2%) due to an increase in seizure frequency (11.9% group A; 8.5% group B; p = 0.7607) and 7 (5.9%) because of adverse events (3.4% group A; 8.5% group B; p = 0.4357).
Baseline patient demographics and characteristics are summarized in Table 1 . Patient mean AE SD age was 15.9 AE 6.80 years and the age range was 4-38 years; the mean weight was 50.7 AE 19.05 kg and the mean age of epilepsy onset was 3.5 AE 3.93 years. Among study population, 16 subjects (12 group A; 4 group B) suffered from generalized seizures, 29 (19 group A; 10 group B) from focal seizures (7 from simple partial seizures, 22 from complex partial seizures), 15 (7 group A; 8 group B) from focal seizures evolving to bilateral convulsive seizures and 58 (21 group A; 37 group B) from mixed seizures. An underlying structural/metabolic etiology was determined in 78 cases (40 group A; 38 group B): neural migration disorder (19) , leukoencephalopathy (11) , encephalitis (9), encephalopathy (9), hydrocephalus (8), cortical cerebral atrophy (6), multiple gliosis (5), poroencephalic lesion (3), hippocampal lesion (2), trisomy 13 (2), ring chromosome 20 (1), right temporal lobectomy (1), bilateral thalamic necrosis (1), hypothalamic hamartoma (1). The remaining 40 cases (19 group A; 21 group B) had no identifiable etiology. More precisely, a structural/metabolic etiology was identified in 8 (50%) of the 16 subjects with generalized seizures, 16 (55.2%) of the 29 patients with focal seizures, 12 (80%) of the 15 subjects with focal seizures evolving to bilateral convulsive seizures and 42 (72.4%) of the 58 patients with mixed seizures. Approximately 9.3% of patients were taking 1 concomitant AED, 58.5% 2 concomitant AEDs, 26.3% 3 concomitant AEDs and 5.9% were taking 4 concomitant AEDs when lacosamide was added to their treatment regimen. In addition to 1-4 concomitant AEDs, a total of 7.6% of patients were also using VNS. 
Efficacy
General efficacy
At 3-month evaluation, of 118 patients entering the maintenance period 56 (47.4%) subjects (47.4% group A; 47.4% group B; p = 0.8537) experienced at least a 50% reduction in seizure frequency ( Fig. 1) , 46 (39%) showed less than 50% reduction in seizure frequency (33.9% group A; 44.1% group B; p = 0.3453) and 6 (5.1%) were seizure free (6.8% group A; 3.4% group B; p = 0.6752); of these 6 patients 5 were taking 2 concomitant AEDs (carbamazepine plus topiramate, carbamazepine plus lamotrigine, carbamazepine plus levetiracetam, diphenylhydantoin plus clonazepam and phenobarbital plus topiramate) and 1 was taking 1 concomitant AED (valproic acid) in addition to lacosamide therapy. Lacosamide appeared to increase seizure frequency in 10 (8.5%) subjects (11.9%) group A; 5.1% group B; p = 0.3214) that were to discontinue treatment. Known seizure types for these subjects were aggravated. Other 6 patients (2 group A, 4 group B) withdrew from the study after the 3-month evaluation because of adverse events. Of 102 patients reaching the 6-month follow-up, only 1 (0.8%) patient (0% group A; 1.7% group B; p = 1) continued to be seizure free, 57 (48.3%) subjects (52.5% group A; 44.1% group B; p = 0.4612) were 50% responders and 42 (35.6%) were non-responders (32.2% group A; 39% group B; p = 0.5641). An increase in seizure frequency was reported in 2 (1.7%) patients (0% group A; 3.4% group B; p = 0.4757) that had to discontinue lacosamide therapy; other 15 patients discontinued treatment after the 6-month follow-up because of lack of efficacy (4 group A, 14 group B) or side effects (1 group B).
Out of 81 patients reaching the 12-month evaluation, 2 (1.7%) subjects (0% group A; 3.4% group B; p = 0.4757) were seizure free, 51 (43.2%) continued to be 50% responders (47.4% group A; 39% group B; p = 0.4573) and 28 (23.7%) did not respond to therapy (30.5% group A; 16.9% group B; p = 0.1298).
Efficacy by seizure type
Data analysis by seizure type showed different responses to lacosamide treatment ( Table 2) .
The 50% responder rates at 3, 6 and 12-month evaluations were 25%, 6.3% and 25% in subjects with generalized seizures; 44.8%, 63.2% and 62.1% in the focal seizure group; 60%, 40% and 26.7% in subjects with focal seizure evolving to bilateral convulsive seizures; 51.7%, 48.3% and 43.1% in patients with mixed seizures. More precisely, within the focal group, 3 of the 7 patients with simple partial seizures and 14 of the 22 subjects with complex partial seizures were 50% responders at 12 months. Interestingly, comparing the 50% responder rates at 12 months between the different seizure type groups, a significant difference was found only between focal and generalized seizure groups (p = 0.0291).
Of 16 patients with generalized epilepsy, seizure freedom was achieved in 12.5%, 6.3% and 6.3% at 3, 6 and 12-month follow-up. Of 29 patients suffering from focal seizures, 13.8% was seizure free at 3 months but no patient was seizure free at 6 and 12 months. Among 15 subjects with focal seizures evolving to bilateral convulsive seizures, no subject achieved 100% reduction in seizure frequency.
The non-responder rates at 3, 6 and 12-month follow-up were 31.2%, 25% and 12.5% in the generalized seizure group; 37.9%, 31% and 17.2% in patients with focal seizures; 40%, 53.3% and 46.7% in subjects with focal seizure evolving to bilateral convulsive seizures; 41.4%, 36.2% and 24.1% in the mixed seizure group.
At 3 months an increase in seizure frequency was observed in 31.2%, 3.5%, 0% and 6.9% of patients with generalized, focal, focal with secondary generalization and mixed seizures, respectively. At 6 months only 3.4% of patients with mixed seizures had an increase in seizure frequency. At 12 months no increase in seizure frequency occurred.
Discontinuation rates over the entire lacosamide treatment period were 56.3% for generalized seizure group, 20.7% for focal seizure group, 26.7% for focal evolving to bilateral convulsive seizure group and 31% for mixed seizure group. Comparing the discontinuation rates between the different seizure type groups, a significant difference (p = 0.0234) was found only between generalized and focal groups.
Safety
Out of 118 treated patients, 35 (29.7%) experienced side effects (30.5% group A; 28.8% group B; p = 1) during the treatment period ( Table 3 ). The most common adverse events were dizziness, headache, somnolence, dyspepsia, vomiting, irritability, and nausea. Other side effects included paresthesia, diplopia, inappetence, balance disorder, fatigue, abdominal pain, lightheadedness.
One patient experienced status epilepticus. Adverse events generally had an onset during the titration period. Most of the reported side effects were mild to moderate in intensity and resolved by slowing the titration rate of lacosamide.
Seven subjects withdrew from the study prematurely during the maintenance period because of side effects: 2 patients in the group A and 5 in the group B. Side effects leading to discontinuation were: vomiting (2 group A; 1 group B), vertigo (3 group A) and status epilepticus (1 group B) .
Overall results of clinical laboratory tests as well as periodic physical examinations, neurological examinations, and assessments of vital signs did not reveal any changes associated with lacosamide treatment. Mean plasma concentrations of the concomitant AEDs as well as body weight were not affected by concomitant intake of lacosamide.
Discussion
This multicenter, prospective, open label treatment study demonstrates that adjunctive therapy with oral lacosamide similarly reduces seizure frequency in pediatric and adult patients with uncontrolled generalized and focal epilepsy. This study confirms the clinical efficacy of lacosamide in refractory epilepsy and corroborates findings from previous studies.
The safety and efficacy of add-on lacosamide in adults with uncontrolled partial-onset seizures were evaluated in three double-blind, placebo-controlled trials and two open-label studies. 9, 10, 16, 17 A favorable outcome of at least 50% seizure reduction was reported in 33-41% of the patients treated with lacosamide 200-600 mg/day. The 50% responder rate in our group of adults with refractory epilepsy (39%) was generally in accordance with these results. In the present study, as well as in the previous clinical trials, [8] [9] [10] 16, 17 lacosamide was well tolerated in adults; adverse events occurred at a low frequency and were related to the nervous and gastrointestinal systems including dizziness, headache, nausea, vomiting, diplopia and somnolence; side effects generally had an onset during the titration period. The discontinuation rate because of side effects ranged from 8.7% to 17% in the previous studies and was similar to that observed in our study (8.5% ).
Postmarketing experience with adjunctive lacosamide in adolescent and adult patients with pharmacoresistant epilepsy yielded similar results. [18] [19] [20] [21] Recent studies conducted in children and adolescents with refractory epilepsy showed a favorable outcome. [11] [12] [13] [14] In the first study, 11 18 patients were enrolled and they completed a mean of 8 months lacosamide treatment, lacosamide was administered orally, in the form of syrup or tablets twice daily with a final dose ranged between 1.7 and 10 mg/kg (mean = 6.3). At the first assessment, 36% of patients experienced a reduction of more than 50% seizure frequency, and two children achieved seizure freedom. Another two studies 12, 13 retrospectively reviewed charts for lacosamide use and seizure frequency outcome in children with focal epilepsy; they respectively identified 16 and 17 patients. In the first study 12 the mean age was 14.9 years and the median maintenance dose of lacosamide was 275 mg/day, while, in the second, 13 children aged 1.5-16 years were treated at doses up to 20 mg/kg/day. Similarly to previous reports in adults, these retrospective studies revealed a favorable outcome in pediatric patients, in particular the first study 12 reported a 39.6% seizure reduction rate. The last study was performed in 2012: Rastogi and Ng 14 reviewed 21 pediatric patients aged up to 17 years who were treated with oral lacosamide as part of a prospective add-on study as adjunctive therapy for refractory epilepsy. Maintenance dosages of lacosamide ranged from 2.4 to 19.4 mg/kg/day. Fifty percent of patients had greater than 50% reduction in seizure frequency and, on the other hand, 50% of patients had generalized epilepsy; at study end, lacosamide was shown to be an effective therapy, particularly for partial-onset seizures. The 50% responder rate reported in those studies, ranging from 35% to 50%, was in accordance to that observed in our group of pediatric patients (47.4%). Adverse events occurred in 37.5-59% of subjects and included mostly somnolence, dizziness, nausea and irritability [11] [12] [13] [14] ; treatment was discontinued in 0-25% of patients because of side effects. [11] [12] [13] [14] In the present study the incidence of adverse events in pediatric population was 29.7% and discontinuation rate due to side effects was 3.4%. The efficacy and safety of lacosamide in pediatric and adult patients were compared in the present study. During the whole treatment period with lacosamide, the 50% responder rates in group A were comparable to those reported in group B. No significant difference in the incidence of side effects between group A and group B was found. The most common side effect reported in group A was dyspepsia in contrast with dizziness observed in group B. Discontinuation rate appeared significantly higher in group B than in group A since most of non-responders in group B compared to those in group A discontinued treatment prematurely due to lack of efficacy.
Based on seizure type, marked differences in efficacy outcomes were observed. Patients suffering from generalized seizures showed a poor response to lacosamide therapy in both groups A and B; on the other hand, the best response to lacosamide treatment was observed in patients suffering from focal seizures, as recently observed by Rastogi and Ng.
14 These subjects showed the lowest discontinuation rate and the highest 50% responder rate in both groups A and B. As recently suggested, the different response to treatment with lacosamide in patients taking 1-4 background AEDs could be linked to its mechanism of action. Stephen et al. demonstrated that the pharmacological effect of lacosamide differs importantly from sodium channel blocking AEDs. 22 In the post hoc exploratory analysis of pooled phase II/III lacosamide clinical trial data, patients taking only AEDs that act on non-sodium channel targets experienced excellent seizure control with the addition of LCM compared with placebo; LCM was well tolerated and had a lower rate of discontinuation for adverse events (8.6%) compared with the pooled phase II/III population (17.5%). 23 In our experience, of 37 patients discontinuing treatment, 14 were taking sodium valproate in addition to lacosamide and most of them discontinued because of aggravated seizures. Since many patients in this study simultaneously received various AEDs, it is difficult to determine whether there is any specific drug synergy with lacosamide.
In conclusion, results from this prospective open label study demonstrate that lacosamide has a similar efficacy and safety profile in children compared with adults. Therefore, our experience suggests that lacosamide could be a very good choice for pediatric patients with uncontrolled seizures. However, the short-term follow-up, as well as the nature of this study and the lack of randomization, does not allow us to make firm conclusions. Large, randomized controlled studies are needed to validate our findings.
